Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile-Reference-Cited by-同舟云学术

Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile

Published:2016-11 Issue: Volume:113 Page:257-264
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Colson Pascal H.,Virsolvy Anne,Gaudard Philippe,Charrabi Azzouz,Corbani Maithé^ORCID,Manière Maxime J.,Richard Sylvain,Guillon Gilles

Funder

INSERM

CNRS

Fondation de France

Publisher

Elsevier BV

Subject

Pharmacology

Reference37 articles.

1. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome;Uriz;J. Hepatol.,2000

2. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome;Gluud;Hepatology (Baltimore, Md.),2010

3. Conversion of triglycylvasopressin to lysine-vasopressin in man;Forsling;J. Endocrinol.,1980

4. Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers;Nilsson;Drugs Exp. Clin. Res.,1990

5. Terlipressin is more effective in decreasing variceal pressure than portal pressure in cirrhotic patients;Romero;J. Hepatol.,2000

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute Kidney Injury in Liver Cirrhosis;Diagnostics;2023-07-13

2. Hepatorenal Syndrome;Medical Clinics of North America;2023-07

3. OCE-205, a Selective V1a Partial Agonist, Reduces Portal Pressure in Rat Models of Portal Hypertension;Journal of Experimental Pharmacology;2023-07

4. Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial;Critical Care Explorations;2023-03-28

5. Selective Partial Agonism of Vasopressin 1a Receptors In Vitro by OCE-205;Journal of Pharmacology and Pharmacotherapeutics;2023-03